It's time to consider a patent reprieve for COVID vaccines

Nature. 2021 Apr;592(7852):7. doi: 10.1038/d41586-021-00863-w.
No abstract available

Keywords: Developing world; Health care; Infection; SARS-CoV-2; Vaccines.

Publication types

  • Editorial
  • Historical Article

MeSH terms

  • COVID-19 / epidemiology
  • COVID-19 / immunology
  • COVID-19 / prevention & control*
  • COVID-19 / transmission
  • COVID-19 Vaccines / economics*
  • COVID-19 Vaccines / supply & distribution*
  • Cooperative Behavior
  • Developed Countries / economics*
  • Developing Countries / economics*
  • Drug Industry / economics*
  • Drug Industry / legislation & jurisprudence
  • History, 20th Century
  • Humans
  • Licensure / legislation & jurisprudence
  • Pandemics / prevention & control
  • Pandemics / statistics & numerical data
  • Patents as Topic / legislation & jurisprudence*
  • Penicillins / economics
  • Penicillins / history
  • Spike Glycoprotein, Coronavirus / genetics
  • Spike Glycoprotein, Coronavirus / immunology
  • United Nations
  • United States / epidemiology
  • World Health Organization / organization & administration
  • World War II

Substances

  • COVID-19 Vaccines
  • Penicillins
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2